Link between genetic variant and smoking cessation meds effectiveness

People with this variant were less likely than those without it to have resumed smoking six months after treatment with bupropion.

The study, published in the September issue of the journal Biological Psychiatry, is a step toward the goal of being able to tailor smoking cessation treatment to individuals based on their unique genetic make-up.

"This study is part of our ongoing commitment to develop more accurate and personalized approaches to medicine," said NIH Director Dr. Elias A. Zerhouni. "This kind of genetic research is helping us to better understand why some people respond to certain smoking cessation treatments, and others don't." -NIH/National Institute on Drug Abuse